Albireo Limited announced that Ron Cooper has joined the company as President and Chief Executive Officer. Mr. Cooper is a global biopharmaceutical leader with a track record of growing businesses, brands and organizations in the U.S. and Europe. He joins Albireo from Bristol-Myers Squibb (BMS), where he was President of Europe.
Albireo Pharma, Inc.
Equities
ALBO
US01345P1066
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |